Evaluation of serum biomarkers IL-17 and CTX for BRONJ: a pilot clinical case-control study
Lee, P.B.; Kiss, A.S.; Nguyen, A.L.; Shi, S.; Sedghizadeh, P.P.; Le Anh, D.
Journal of the California Dental Association 41(11): 819-823
2013
ISSN/ISBN: 1043-2256 PMID: 24341133 Document Number: 664188
A serious complication of bisphosphonate (BP) therapy is BP-related osteonecrosis of the jaw (BRONJ). Currently, no biomarkers exist to identify patients at risk. We evaluated whether interleukin-17 and C-telopeptide correlate with BRONJ development. We conducted a case-control study using patients with a history of BP therapy. Quantitative enzyme-linked immunosorbent assay and Student's t-test were done. Both markers were significantly higher in BRONJ, suggesting altered immune responses and bone remodeling may play roles in BRONJ development.